{
  "model": "glm-5",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "All four output files are present and valid JSON. Let me provide the completion checklist:\n\n## Completion Checklist\n\n- [x] `output/study_overview.json` - Written successfully with paper metadata, core question, 5 cohorts, and 5 major limitations\n- [x] `output/quantitative_findings.json` - Written successfully with 6 quantitative findings and 4 control/null results with line refs\n- [x] `output/claim_audit.json` - Written successfully with 5 claims (C01-C05), each with quotes, line refs, strength ratings, and caveats\n- [x] `output/public_summary.json` - Written successfully with headline, plain language summary, what_is_new (3 items), why_caution_is_needed (4 items), glossary (6 terms), and open_questions (5 items)",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": null
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "chatcmpl-tool-86f3ceab41b5b047"
          }
        ],
        "usage": {
          "promptTokens": 1175,
          "cachedTokens": 0,
          "responseTokens": 43,
          "totalTokens": 1218
        },
        "costUsd": 0.0013126000000000001
      },
      {
        "step": 2,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": null
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "chatcmpl-tool-89b3d2f9d6165157"
          }
        ],
        "usage": {
          "promptTokens": 1615,
          "cachedTokens": 0,
          "responseTokens": 58,
          "totalTokens": 1673
        },
        "costUsd": 0.0018005999999999999
      },
      {
        "step": 3,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "chatcmpl-tool-af8ddee94d42db5d"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "chatcmpl-tool-90875b3b3e39a641"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "chatcmpl-tool-9254a8b981ac0d8e"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "chatcmpl-tool-865bae380f0251e3"
          }
        ],
        "usage": {
          "promptTokens": 2714,
          "cachedTokens": 0,
          "responseTokens": 130,
          "totalTokens": 2844
        },
        "costUsd": 0.00313
      },
      {
        "step": 4,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "Now I'll draft all four output files based on the report and schemas, then write them.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\n    },\n    {\n      \"id\": \"human-retrospective-full\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of metastatic patients who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of metastatic patients who had not received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "chatcmpl-tool-9647cb2e9944765b"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3% in comparator\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6% in comparator\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0 in comparator\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x in comparator\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x in comparator\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "chatcmpl-tool-8f678f62b05eb03a"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, showing the effect is IFN-dependent.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Interferon-associated antigen processing increases, broadening the peptide repertoire on MHC-I and improving tumor visibility to T cells.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors; PD-L1 upregulation may vary by tumor type.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mouse models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\n          \"line_ref\": \"L19\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and tumor-type heterogeneity limits generalization.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic cancer patients receiving ICI treatment.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Human vaccinated subgroup: 43 patients.\",\n          \"line_ref\": \"L22\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing varied across patients.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "chatcmpl-tool-b9df53e9e54f8252"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists discovered that delivering an mRNA vaccine directly into tumors can make cancer treatments called immune checkpoint inhibitors work better. In mice with tumors, this combination treatment led to stronger immune responses and better tumor control. The vaccine triggers a signaling pathway involving interferon, which helps the immune system recognize cancer cells more effectively. Looking back at medical records, cancer patients who had previously received a SARS-CoV-2 mRNA vaccine seemed to respond better to immunotherapy than those who had not. However, this human finding needs confirmation through carefully designed prospective studies before doctors should change how they treat patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-b427f9ef58fbb336"
          }
        ],
        "usage": {
          "promptTokens": 5749,
          "cachedTokens": 0,
          "responseTokens": 4018,
          "totalTokens": 9767
        },
        "costUsd": 0.0186066
      },
      {
        "step": 5,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combo\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-full\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of metastatic patients who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of metastatic patients who had not received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "chatcmpl-tool-aab04f2abc5e1a17"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3% in comparator\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6% in comparator\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0 in comparator\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x in comparator\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x in comparator\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "chatcmpl-tool-ba3faa7433aaac42"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL14:           \"line_ref\": \"L31\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, showing the effect is IFN-dependent.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"Interferon-associated antigen processing increases, broadening the peptide repertoire on MHC-I and improving tumor visibility to T cells.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\nL26:           \"line_ref\": \"L43\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL30:           \"line_ref\": \"L44\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL34:           \"line_ref\": \"L29\"\nL35:         }\nL36:       ],\nL37:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL38:     },\nL39:     {\nL40:       \"claim_id\": \"C03\",\nL41:       \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\nL42:       \"strength\": \"moderate\",\nL43:       \"evidence\": [\nL44:         {\nL45:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL46:           \"line_ref\": \"L45\"\nL47:         },\nL48:         {\nL49:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL50:           \"line_ref\": \"L32\"\nL51:         }\nL52:       ],\nL53:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors; PD-L1 upregulation may vary by tumor type.\"\nL54:     },\nL55:     {\nL56:       \"claim_id\": \"C04\",\nL57:       \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mouse models.\",\nL58:       \"strength\": \"strong\",\nL59:       \"evidence\": [\nL60:         {\nL61:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL62:           \"line_ref\": \"L46\"\nL63:         },\nL64:         {\nL65:           \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\nL66:           \"line_ref\": \"L19\"\nL67:         }\nL68:       ],\nL69:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and tumor-type heterogeneity limits generalization.\"\nL70:     },\nL71:     {\nL72:       \"claim_id\": \"C05\",\nL73:       \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic cancer patients receiving ICI treatment.\",\nL74:       \"strength\": \"moderate\",\nL75:       \"evidence\": [\nL76:         {\nL77:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL78:           \"line_ref\": \"L30\"\nL79:         },\nL80:         {\nL81:           \"quote\": \"Human vaccinated subgroup: 43 patients.\",\nL82:           \"line_ref\": \"L22\"\nL83:         }\nL84:       ],\nL85:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing varied across patients.\"\nL86:     }\nL87:   ]\nL88: }",
            "callId": "chatcmpl-tool-a9c193db346fa3fd"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists discovered that delivering an mRNA vaccine directly into tumors can make cancer treatments called immune checkpoint inhibitors work better. In mice with tumors, this combination treatment led to stronger immune responses and better tumor control. The vaccine triggers a signaling pathway involving interferon, which helps the immune system recognize cancer cells more effectively. Looking back at medical records, cancer patients who had previously received a \nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-b7a6d13de5669177"
          }
        ],
        "usage": {
          "promptTokens": 8635,
          "cachedTokens": 0,
          "responseTokens": 135,
          "totalTokens": 8770
        },
        "costUsd": 0.009067
      },
      {
        "step": 6,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "I see the public_summary.json file has a malformed JSON structure - the plain_language_summary is truncated. Let me fix this:",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists discovered that delivering an mRNA vaccine directly into tumors can make cancer treatments called immune checkpoint inhibitors work better. In mice with tumors, this combination treatment led to stronger immune responses and better tumor control. The vaccine triggers a signaling pathway involving interferon, which helps the immune system recognize cancer cells more effectively. Looking back at medical records, cancer patients who had previously received a SARS-CoV-2 mRNA vaccine seemed to respond better to immunotherapy than those who had not. However, this human finding needs confirmation through carefully designed prospective studies before doctors should change how they treat patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-bd90146602ef169e"
          }
        ],
        "usage": {
          "promptTokens": 12216,
          "cachedTokens": 0,
          "responseTokens": 953,
          "totalTokens": 13169
        },
        "costUsd": 0.0152656
      },
      {
        "step": 7,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists discovered that delivering an mRNA vaccine directly into tumors can make cancer treatments called immune checkpoint inhibitors work better. In mice with tumors, this combination treatment led to stronger immune responses and better tumor control. The vaccine triggers a signaling pathway involving interferon, which helps the immune system recognize cancer cells more effectively. Looking back at medical records, cancer patients who had previously received a \nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-b0cbf3eea491580c"
          }
        ],
        "usage": {
          "promptTokens": 12953,
          "cachedTokens": 0,
          "responseTokens": 38,
          "totalTokens": 12991
        },
        "costUsd": 0.013074599999999999
      },
      {
        "step": 8,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "The file appears to still have issues. Let me try writing with a slightly shorter plain_language_summary that's still within schema bounds:",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a retrospective analysis of patient records, those who had previously received a SARS-CoV-2 mRNA vaccine appeared to respond better to immunotherapy. However, these human findings need confirmation through properly designed clinical trials before any changes to standard care can be recommended.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-912f0a444e95f5a7"
          }
        ],
        "usage": {
          "promptTokens": 13767,
          "cachedTokens": 0,
          "responseTokens": 764,
          "totalTokens": 14531
        },
        "costUsd": 0.0162118
      },
      {
        "step": 9,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a retrospective analysis of patient records, those who had previously received a SARS-CoV-2 mRNA vaccine appeared to respond better to immunotherapy. Howeve\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-b2995e1d5b30a5eb"
          }
        ],
        "usage": {
          "promptTokens": 14492,
          "cachedTokens": 8634,
          "responseTokens": 38,
          "totalTokens": 14530
        },
        "costUsd": 0.0077063999999999995
      },
      {
        "step": 10,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had previously received a SARS-CoV-2 mRNA vaccine appeared to respond better to immunotherapy. However, these human findings need confirmation through properly designed clinical trials before any changes to standard care can be recommended.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-a1b54bb083d61db2"
          }
        ],
        "usage": {
          "promptTokens": 15315,
          "cachedTokens": 0,
          "responseTokens": 710,
          "totalTokens": 16025
        },
        "costUsd": 0.017587
      },
      {
        "step": 11,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had previously received a SARS-CoV-2 mRNA vaccine appeared to respond better to immunotherapy. However, these human f\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-b9cca05e791d7a40"
          }
        ],
        "usage": {
          "promptTokens": 16013,
          "cachedTokens": 14491,
          "responseTokens": 51,
          "totalTokens": 16064
        },
        "costUsd": 0.0045834
      },
      {
        "step": 12,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had prior SARS-CoV-2 mRNA vaccination appeared to respond better to immunotherapy. These findings need confirmation through properly designed clinical trials.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-99120a58d1ef05c7"
          }
        ],
        "usage": {
          "promptTokens": 16838,
          "cachedTokens": 0,
          "responseTokens": 729,
          "totalTokens": 17567
        },
        "costUsd": 0.019170799999999998
      },
      {
        "step": 13,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve the effectiveness of cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had prior SARS-CoV-2 mRNA vaccination appeared to respond better to immunotherapy. These findings need confirmation t\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-bed3359d7c5f8994"
          }
        ],
        "usage": {
          "promptTokens": 17522,
          "cachedTokens": 0,
          "responseTokens": 35,
          "totalTokens": 17557
        },
        "costUsd": 0.017634
      },
      {
        "step": 14,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had prior SARS-CoV-2 mRNA vaccination appeared to respond better to immunotherapy. These findings require confirmation through clinical trials.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-9b7110e5b5b5efc8"
          }
        ],
        "usage": {
          "promptTokens": 18345,
          "cachedTokens": 0,
          "responseTokens": 752,
          "totalTokens": 19097
        },
        "costUsd": 0.0207514
      },
      {
        "step": 15,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize and attack cancer cells. In a review of patient records, those who had prior SARS-CoV-2 mRNA vaccination appeared to respond better to immunotherapy. These findings require confirmation through clinical tr\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-a805d0378601557b"
          }
        ],
        "usage": {
          "promptTokens": 19024,
          "cachedTokens": 0,
          "responseTokens": 54,
          "totalTokens": 19078
        },
        "costUsd": 0.0191968
      },
      {
        "step": 16,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\n  \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize cancer cells. Patient records suggest prior SARS-CoV-2 mRNA vaccination may improve immunotherapy response. These findings require confirmation through clinical trials before changing practice.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\n    \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\n    \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\n    \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\n    \"Results from mouse models do not always translate directly to human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\n    \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\n    \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\n    \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-8b4fc6791ef00401"
          }
        ],
        "usage": {
          "promptTokens": 19846,
          "cachedTokens": 0,
          "responseTokens": 769,
          "totalTokens": 20615
        },
        "costUsd": 0.022306799999999998
      },
      {
        "step": 17,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy work better against tumors\",\nL3:   \"plain_language_summary\": \"Scientists found that injecting an mRNA vaccine into tumors can improve cancer immunotherapy. In mice, this combination triggered stronger immune responses and better tumor control. The vaccine activates interferon signaling, which helps the immune system recognize cancer cells. Patient records suggest prior SARS-CoV-2 mRNA vaccination may improve immunotherapy response. These findings require confirmation through clinical trials before changing practice.\",\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination can prime tumors to be more visible to the immune system by expanding the range of proteins displayed on cell surfaces.\",\nL6:     \"The combination of mRNA vaccination and anti-PD-L1 checkpoint blockade works through type I interferon signaling to improve tumor control.\",\nL7:     \"Retrospective human data suggests prior SARS-CoV-2 mRNA vaccination may improve outcomes for patients receiving immune checkpoint inhibitor therapy.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study looked back at existing medical records rather than tracking patients prospectively, so other factors could explain the apparent benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to know the best approach.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting how broadly the findings can be applied.\",\nL13:     \"Results from mouse models do not always translate directly to human cancers.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers genetic instructions to cells, prompting them to produce proteins that train the immune system to recognize threats.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Immune checkpoint inhibitor\",\nL22:       \"definition\": \"A type of cancer drug that releases brakes on the immune system, allowing T cells to attack tumors more effectively.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein on tumor cells that binds to PD-1 on immune cells, suppressing their ability to attack the cancer.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, helping the immune system identify infected or cancerous cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Signaling proteins produced by cells in response to viral infections or other threats, helping coordinate immune defenses.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"CD8+ T cells\",\nL38:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor therapy?\",\nL44:     \"Does the sensitization effect depend on specific tumor types or baseline immunogenicity?\",\nL45:     \"Can systemic mRNA vaccination achieve similar tumor sensitization, or is intratumoral delivery necessary?\",\nL46:     \"Would repeated mRNA vaccination provide sustained benefit during long-term immunotherapy?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-a7ccbc485d69fee1"
          }
        ],
        "usage": {
          "promptTokens": 20517,
          "cachedTokens": 0,
          "responseTokens": 54,
          "totalTokens": 20571
        },
        "costUsd": 0.0206898
      },
      {
        "step": 18,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "The JSON appears valid now. Let me verify the files are complete by checking all four outputs exist and are valid JSON:",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "chatcmpl-tool-a9bc03bfacede739"
          }
        ],
        "usage": {
          "promptTokens": 21331,
          "cachedTokens": 13766,
          "responseTokens": 234,
          "totalTokens": 21565
        },
        "costUsd": 0.011067
      },
      {
        "step": 19,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combo\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-full\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subgroup of metastatic patients who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subgroup of metastatic patients who had not received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "chatcmpl-tool-a5dc4ab8aaa40d57"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3% in comparator\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6% in comparator\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0 in comparator\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x in comparator\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x in comparator\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "chatcmpl-tool-94ddab07fd97b4ef"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL14:           \"line_ref\": \"L31\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, showing the effect is IFN-dependent.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"Interferon-associated antigen processing increases, broadening the peptide repertoire on MHC-I and improving tumor visibility to T cells.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\nL26:           \"line_ref\": \"L43\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL30:           \"line_ref\": \"L44\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL34:           \"line_ref\": \"L29\"\nL35:         }\nL36:       ],\nL37:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL38:     },\nL39:     {\nL40:       \"claim_id\": \"C03\",\nL41:       \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\nL42:       \"strength\": \"moderate\",\nL43:       \"evidence\": [\nL44:         {\nL45:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL46:           \"line_ref\": \"L45\"\nL47:         },\nL48:         {\nL49:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL50:           \"line_ref\": \"L32\"\nL51:         }\nL52:       ],\nL53:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors; PD-L1 upregulation may vary by tumor type.\"\nL54:     },\nL55:     {\nL56:       \"claim_id\": \"C04\",\nL57:       \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mouse models.\",\nL58:       \"strength\": \"strong\",\nL59:       \"evidence\": [\nL60:         {\nL61:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL62:           \"line_ref\": \"L46\"\nL63:         },\nL64:         {\nL65:           \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\nL66:           \"line_ref\": \"L19\"\nL67:         }\nL68:       ],\nL69:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and tumor-type heterogeneity limits generalization.\"\nL70:     },\nL71:     {\nL72:       \"claim_id\": \"C05\",\nL73:       \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic cancer patients receiving ICI treatment.\",\nL74:       \"strength\": \"moderate\",\nL75:       \"evidence\": [\nL76:         {\nL77:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL78:           \"line_ref\": \"L30\"\nL79:         },\nL80:         {\nL81:           \"quote\": \"Human vaccinated subgroup: 43 patients.\",\nL82:           \"line_ref\": \"L22\"\nL83:         }\nL84:       ],\nL85:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing varied across patients.\"\nL86:     }\nL87:   ]\nL88: }",
            "callId": "chatcmpl-tool-a38cc154bc6330c7"
          }
        ],
        "usage": {
          "promptTokens": 21404,
          "cachedTokens": 0,
          "responseTokens": 120,
          "totalTokens": 21524
        },
        "costUsd": 0.021788
      },
      {
        "step": 20,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "All four output files are present and valid JSON. Let me provide the completion checklist:\n\n## Completion Checklist\n\n- [x] `output/study_overview.json` - Written successfully with paper metadata, core question, 5 cohorts, and 5 major limitations\n- [x] `output/quantitative_findings.json` - Written successfully with 6 quantitative findings and 4 control/null results with line refs\n- [x] `output/claim_audit.json` - Written successfully with 5 claims (C01-C05), each with quotes, line refs, strength ratings, and caveats\n- [x] `output/public_summary.json` - Written successfully with headline, plain language summary, what_is_new (3 items), why_caution_is_needed (4 items), glossary (6 terms), and open_questions (5 items)",
        "toolCalls": [],
        "usage": {
          "promptTokens": 24174,
          "cachedTokens": 0,
          "responseTokens": 401,
          "totalTokens": 24575
        },
        "costUsd": 0.0254572
      }
    ],
    "totalCostUsd": 0.2864074
  }
}
